Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.
Vertex Pharmaceuticals selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients.
Ferring Pharmaceuticals Inc. announced that the U.S. FDA approved Zomacton (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.
Following a failed Phase III vaccine for stem cell transplant recipients, San Diego-based Vical Incorporated is slashing 54 percent of its employees and focusing the company’s remaining resources on two mid-stage candidates.
Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.
Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
The Inception Companies announce that Shaun Urban, former Managing Partner of Ogilvy CommonHealth, joined the organization as President.
Bellicum Pharmaceuticals Inc. said the FDA placed a clinical hold on U.S. trials of the company’s experimental cancer drug after three cases of brain disease linked to head trauma.